CLINICAL_TRIALS
trial_result
· 2024-06-13
Clinical Trial Update: Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. [Phase 3]
Summary
Phase 3 trial results for Reparixin in hospitalized patients with severe COVID-19 pneumonia have been completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dompé Farmaceutici S.p.A | Conditions: Pneumonia, Viral | Phase 3 | Status: COMPLETED | Results posted: 2024-06-13